# Amplifier Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amplifier-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.amplifier-tx.com/
- Latest round: Series A (Oct 17, 2023)
- Investors on record: 3

## About

Based in New York, US, and founded in 2013, Amplifier TX AB d.b.a Amplifier Therapeutics is a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging, including metabolic conditions, cardiovascular diseases, kidney diseases, and cancer. In October 2023, Amplifier Therapeutics raised series A funding led by investor Cambrian Biopharma, with participation from other investors Future Ventures and RA Capital Management. 

The company engages in the development of a compound called ATX-304, which activates AMPK. ATX-304 has the potential to treat various conditions, particularly those related to aging, such as heart and kidney diseases, diabetes, and cancer. It may also be a potential treatment for obesity.

## Funding rounds

- Series A, Oct 17, 2023 — RA Capital Management, Future Ventures, Cambrian Biopharma

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Future Ventures — Series A
- Cambrian Biopharma (https://capitalatlas.ai/funds/cambrian-biopharma) — Series A